ArticlePediatric research2025
Plasma extracellular vesicles-derived microRNAs provide potential biomarkers in distinguishing between focal cortical dysplasia type I and II.
Article in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreoperative pathological information of focal cortical dysplasia (FCD) is critical for surgical planning, but non-invasive diagnostic methods are currently unavailable. This study aimed to identify potential biomarkers for FCD subtyping by screening microRNAs (miRNAs) in plasma extracellular vesicles (EVs).
methodsWe identified the most representative pathological subtypes based on the clinical characteristics of FCD Type I and II in 439 pediatric FCD patients. Differential expression analysis of miRNA was performed in plasma EVs and brain tissues from samples of representative pathological subtypes. Potential biomarkers and downstream target genes were identified by integrating brain tissue transcriptome data. Target genes underwent enrichment and protein-protein interaction analyses, with immunohistochemical validation in brain tissue.
resultsFCD Ia and IIb represent the clinical characteristics between FCD Type I and II, respectively. Eight differentially expressed miRNAs common to plasma EVs and brain tissue were identified, which had 241 target genes in brain tissue. These target genes were enriched in immune-related functions, cytokine-cytokine receptor interaction, p53, and NF-κB signaling pathways. Among nine core proteins, CDKN1A and CD274 were confirmed to be elevated in FCD IIb lesions compared to FCD Ia.
conclusionDifferentially expressed miRNAs in extracellular vesicles may serve as potential non-invasive biomarkers for FCD subtyping. IMPACT: Lesional characteristics, surgical approaches, and prognosis are different between FCD type I and II. Eight differentially expressed miRNAs in plasma extracellular vesicles between FCD type I and II were identified. Target genes of these miRNAs were significantly enriched in immune and inflammatory responses and cytokine pathways. The identified miRNAs may represent potential pre-operative biomarkers for FCD subtyping, potentially guiding surgical strategies and outcome prediction, especially for FCD type II. Extracellular vesicle-mediated immune responses may differ between FCD type I and II, offering insight into FCD pathogenesis, epileptogenic mechanisms, and the identification of novel therapeutic targets.
Identifiers
41177813What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.